News for AIM ImmunoTech Inc Stock (AIM)

AIM ImmunoTech hails positive data from program evaluating Ampligen as maintenance therapy for pancreatic cancer

Proactive Investors • 07/20/22

AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

GlobeNewsWire • 07/20/22

AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid

GlobeNewsWire • 07/18/22

AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series

GlobeNewsWire • 07/14/22

AIM ImmunoTech inks lease deal for new state-of-the-art product development and testing facility in New Jersey

Proactive Investors • 06/21/22

AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing

GlobeNewsWire • 06/21/22

AIM ImmunoTech boosts intellectual property with new Netherlands utility patent covering Ampligen and dsRNA products aimed at COVID-19

Proactive Investors • 06/13/22

AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention

GlobeNewsWire • 06/13/22

AIM ImmunoTech to file Investigational New Drug application for Ampligen to treat long COVID

Proactive Investors • 05/18/22

AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewsWire • 05/16/22

AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact' on May 19, 2022

GlobeNewsWire • 05/12/22

AIM ImmunoTech says Ampligen data supports synergistic potential with checkpoint blockade therapies

Proactive Investors • 04/21/22

AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies

GlobeNewsWire • 04/21/22

AIM ImmunoTech engages CRO Amarex Clinical Research to manage Phase 2 of Ampligen study

Proactive Investors • 04/12/22

AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer

GlobeNewsWire • 04/12/22

AIM ImmunoTech reports positive data from Phase 2a study evaluating Ampligen as part of a regimen treating colorectal cancer that has spread to the liver

Proactive Investors • 04/11/22

Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes

PennyStocks • 04/11/22

AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting

Benzinga • 04/11/22

AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

GlobeNewsWire • 04/11/22

AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver

GlobeNewsWire • 04/11/22

AIM ImmunoTech reports ‘strong' balance sheet to fund operations and clinical development programs through 2023

Proactive Investors • 04/01/22

AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewsWire • 03/31/22

AIM ImmunoTech says data from Ampligen study on pancreatic cancer accepted for presentation at upcoming IHPBA World Congress

Proactive Investors • 03/28/22

AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress

GlobeNewsWire • 03/28/22

AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell P

GlobeNewsWire • 03/24/22